Stay updated on Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Sign up to get notified when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.

Latest updates to the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page
- Check3 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the page.SummaryDifference0.0%

- Check10 days agoChange DetectedDeleted the citation for Wei AH et al. on risk stratification of low-dose cytarabine and venetoclax in AML (Blood Advances, 2026).SummaryDifference0.0%

- Check17 days agoChange DetectedAdded Revision v3.4.3 and removed Revision v3.4.2.SummaryDifference0.0%

- Check25 days agoChange DetectedA new Blood Advances 2026 publication citation is added to the Publications section, and the 2025 ahead-of-print citation is removed.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision: v3.4.1 label is added to the page footer, and Revision: v3.4.0 label is removed.SummaryDifference0.0%

Stay in the know with updates to Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.